Chi-Med presents pre-clinical data at ASH

Hutchison China MediTech says data from a recent pre-clinical study, investigating the in vitro and in vivo anti-tumor activities of novel Spleen Tyrosine Kinase (inhibitor, HMPL-523, was presented at the annual meeting of the American Society of Hematology in San Diego. Syk, a non-receptor type of tyrosine kinase, plays a pivotal role in the regulation of the B-cell receptor (BCR) signaling pathway, which regulates proliferation, differentiation and survival of B lymphocytes. The abnormal activation of BCR signaling is closely related to transformation and development of B-cell lymphoma.

Story provided by